%0 Journal Article
%T Advances in Systemic Lupus Erythematosus Treatment With Monoclonal Antibodies: A Mini-Review.
%A Zavaleta-Monestel E
%A Arrieta-Vega D
%A Rojas-Chinchilla C
%A Campos-Hernández J
%A García-Montero J
%A Quesada-Villaseñor R
%A Anchía-Alfaro A
%A Arguedas-Chacón S
%J Cureus
%V 16
%N 7
%D 2024 Jul
%M 39114252
暂无%R 10.7759/cureus.64090
%X Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs and systems. It is characterized by the production of abnormal antibodies that attack healthy cells and tissues. The disease presents a wide range of symptoms and severity, from mild to severe. Diagnosis can be complex, but the classification criteria of the American College of Rheumatology (ACR) help to facilitate it. Incidence and prevalence vary considerably worldwide, mainly affecting adult women between the third and fourth decades of life, although it can also occur in childhood. The prognosis of SLE has improved over time, but there is still a risk of irreversible organ damage. Treatment is individualized for each patient and is based on immunosuppression and the use of corticosteroids. Biological therapies, such as monoclonal antibodies, have emerged as a more specific alternative. Methotrexate, antimalarials, glucocorticoids, immunosuppressants, and monoclonal antibodies are some of the medications used to treat SLE. New therapeutic strategies are currently being developed, such as targeted therapies, immunomodulators, and biological agents. Treatment adherence, monitoring, and regular follow-up are important aspects of SLE management. This article aims to describe the characteristics of the new monoclonal antibody therapies that exist for the management of SLE.